{
    "Trade/Device Name(s)": [
        "BD GeneOhm MRSA ACP Assay"
    ],
    "Submitter Information": "BD Diagnostics (GeneOhm Sciences Canada Inc.)",
    "510(k) Number": "K093346",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042357",
        "K070462"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQX"
    ],
    "Summary Letter Date": "October 22, 2009",
    "Summary Letter Received Date": "October 26, 2009",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.1640"
    ],
    "Regulation Name(s)": [
        "Antimicrobial susceptibility test powder"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Methicillin-resistant Staphylococcus aureus (MRSA) DNA"
    ],
    "Specimen Type(s)": [
        "Nasal swab"
    ],
    "Specimen Container(s)": [
        "Swab"
    ],
    "Instrument(s)/Platform(s)": [
        "SmartCycler II"
    ],
    "Method(s)/Technology(ies)": [
        "Polymerase chain reaction (PCR)",
        "Fluorogenic target-specific hybridization probes"
    ],
    "Methodologies": [
        "Nucleic acid amplification",
        "Genotypic detection",
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for BD GeneOhm MRSA ACP Assay, a qualitative PCR test for direct detection of MRSA DNA from nasal swabs.",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test for direct detection of MRSA DNA from nasal swabs in patients at risk for nasal colonization; aids prevention and control of MRSA infections in healthcare settings; not for diagnosis or treatment monitoring.",
    "fda_folder": "Microbiology"
}